

Weekly Evidence Surveillance May 10th 2024

Source	Item	Pub Date	Details
ECDC	Influenza virus characterization - Summary Europe, March 2024 (europa.eu)	08/05/2024	Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024 informed the WHO influenza vaccine composition meeting (VCM) in February 2024 when recommendations were made for the Northern hemisphere (NH) 2024-2025 influenza season.
ECDC	Increase of pertussis cases in the EU/EEA (europa.eu)	08/10/2024	After a few years of limited circulation in the EU/EEA, particularly during the COVID-19 pandemic, more than 25 000 cases of pertussis were reported in 2023, and more than 32 000 between January and March 2024. Similar numbers were observed in 2016 (41 026) and 2019 (34 468).
ECDC	Cross-agency One Health task force framework for action (europa.eu)	07/05/2024	Following the joint statement from the Executive Directors of the European Centre for Disease Prevention and Control (ECDC), the European Chemicals Agency (ECHA), the European Environment Agency (EEA), the European Food Safety Authority (EFSA) and the European Medicines Agency (EMA) on how to deliver 'Cross-agency knowledge for One Health Action', the Cross-agency One Health task force has prepared this framework for action. The document outlines the common vision and objectives of the task force and lists a set of concrete actions to achieve them.
ECDC	Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals – 2022-2023 (europa.eu)	06/05/2024	In 2022–2023, 28 EU/EEA countries and three Western Balkan countries (Kosovo*, Montenegro and Serbia) participated in the third ECDC point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European acute care hospitals. Data from a total of 1 623 hospitals were submitted to ECDC. Of these, 309 504 patients from 1 332 hospitals were included in the final European sample for analysis. Data from a single ward were collected on a single day. The total time frame for data collection for all wards of a single hospital was 11 days on average (median eight days). Aggregated results were only reported

			for the EU/EEA, corresponding to 293 581 patients from 1 250 hospitals.
WHO	Joint external evaluation of the International Health Regulations (2005) core capacities for Estonia: mission report, 9-13 October 2023	09/05/2024	The aim of this exercise was to equip Estonian authorities with actionable information for improving implementation of the International Health Regulations (IHR) 2005, encompassing cost estimates, high-level commitment and accountability.
WHO	Long-term care for older people: package for universal health coverage (who.int)	08/05/2024	This publication includes a list of LTC interventions that all countries could consider, prioritize and provide and could integrate within health and social care sectors, depending on their context.
WHO	Strengthening pandemic preparedness and response through integrated modelling (who.int)	08/05/2024	This guide was prepared for policy-makers at all levels of government and those who support them, such as technical units, experts and scientific advisory groups and teams responsible for collecting and managing various sources of national and subnational data.
WHO	Digital adaptation kit for tuberculosis: operational requirements for implementing WHO recommendations in digital systems	08/05/2024	Digital Adaptation Kits (DAKs) are part of WHO's SMART guidelines initiative. This aims to ensure that the content of WHO's evidence-based guidelines is accurately reflected in the digital systems being used at country level.
WHO	Global report on neglected tropical diseases 2024 (who.int)	05/05/2024	This document is the second in a series of global reports describing progress towards the 2030 targets set in Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. It describes a wide range of activities, accomplishments and challenges across the portfolio of NTDs and across all six WHO regions.
WHO	A case study on the ecosystem for local production of pharmaceuticals, vaccines and biologicals (Various publications)	06/05/2024	Various case studies. Pakistan, Kenya, Tunisia, Bangladesh, Nigeria
CDC	Readout of CDC Call with State Public Health Partners Regarding Avian Influenza and Farmworker Protection CDC Online Newsroom CDC	06/05/2024	CDC asked that jurisdictions make PPE available to workers on dairy farms, poultry farms, and in slaughterhouses. Specifically, CDC asked state health departments to work with their state agriculture department counterparts and partners in communities, such as farmworker organizations, that can help coordinate and facilitate PPE distributions.

UKHSA	Pertussis epidemiology in England 2024 - GOV.UK (www.gov.uk)	10/05/2024	Updated to include data to end March 2024.
UKHSA	Pertussis oral fluid laboratory request form and instructions - GOV.UK (www.gov.uk)	10/05/2024	Updated. Combined laboratory request form and template letter, updated pictogram and instructions for HPTs.
UKHSA	UKHSA Advisory Board: agenda - GOV.UK (www.gov.uk)	09/05/2024	The agenda and papers for the UK Health Security Agency (UKHSA) board meeting of 8 May 2024.
UKHSA	Whooping cough cases continue to rise - GOV.UK (www.gov.uk)	09/05/2024	Press release. New data published today by the UK Health Security Agency (UKHSA) shows cases of whooping cough continue to increase with 1,319 cases confirmed in March.
UKHSA	Mpox outbreak: epidemiological overview - GOV.UK (www.gov.uk)	09/05/2024	Overview of the current mpox (monkeypox) outbreak in the UK.
UKHSA	Our governance - UK Health Security Agency - GOV.UK (www.gov.uk)	08/05/2024	Details of framework agreement, leadership structure and advisory board information.
UKHSA	UKHSA Commercial and Partnerships - GOV.UK (www.gov.uk)	08/05/2024	This guidance is designed to help UKHSA customers and partners to navigate engaging and working with us and to signpost upcoming events and opportunities.
UKHSA	New 5-year plan to combat antimicrobial resistance - GOV.UK (www.gov.uk)	08/05/2024	Press release: The government has announced its new national action plan on antimicrobial resistance to protect people and animals from the risk of drug-resistant infections.
UKHSA	Urinary tract infection: diagnostic tools for primary care - GOV.UK (www.gov.uk)	08/05/2024	Public consultation. Quick reference tools for primary care providers for diagnosing and understanding culture results for urinary tract infections (UTIs).
UKHSA	Communal accommodation settings: infectious disease transmission - GOV.UK (www.gov.uk)	07/05/2024	This rapid review summarises available evidence on infectious disease transmission risk in communal accommodation settings.
NICE	Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 Guidance NICE	08/05/2024	New guidance. Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
NICE	COVID-19 rapid guideline: managing COVID-19 Guidance NICE	08/05/2024	Updated guideline. In May 2024, NICE updated the guidance on remdesivir and added a new recommendation on tixagevimab plus cilgavimab in line with NICE's technology appraisal guidance on remdesivir and tixagevimab plus cilgavimab for treating COVID-19.

ESRI	What is preventing individual climate action? Impact awareness and perceived difficulties in changing transport and food behaviour ESRI	09/05/2024	This report examines awareness of and perceived difficulty with individual behaviour change with respect to two actions associated with high levels of emissions: transport and food choice.
PH Ontario	Measles in Ontario (publichealthontario.ca)	09/05/2024	Epidemiology of measles in Ontario in 2024, as well as trends over time for 2013-2023.
PH Ontario	Action IPAC Activities Support IPAC Practices Congregate Living Settings (publichealthontario.ca)	08/05/2024	The Action IPAC Series was a joint initiative of Ontario's Ministry of Health and Public Health Ontario in 2021. The activities in the series addressed basic IPAC concepts that are important for everyone in congregate settings (both healthcare and non-healthcare focused) to follow, and were designed to be easily implemented by anyone, not just an IPAC designate with years of experience.
HIQA	Evidence review of universal ultrasound screening for developmental dysplasia of the hip (DDH) in infants in Ireland HIQA	10/05/2024	At the request of the National Screening Advisory Committee (NSAC), the Health Technology Assessment (HTA) Directorate within the Health Information and Quality Authority (HIQA) agreed to undertake an evidence review of universal screening for developmental dysplasia of the hip (DDH). The findings of this evidence review were presented to the NSAC to inform its recommendation to the Minister for Health.
PHS	Interim guidance for health protection teams for management of human cases of highly pathogenic avian influenza H5N1 in bovines - Interim guidance for health protection teams for management of human cases of highly pathogenic avian influenza H5N1 in bovines - Publications - Public Health Scotland	09/05/2024	New interim guidance published
PHS	MMR vaccine leaflet for use in prisons - Publications - Public Health Scotland	09/05/2024	A leaflet about the measles, mumps and rubella (MMR) vaccine for use in a prison setting.
PHS	Public Health Alert Xylazine 2024 - Rapid Action Drug Alerts and Response (RADAR) Alerts - Publications - Public Health Scotland	09/05/2024	Xylazine is a non-opioid tranquiliser used in veterinary medicine as a sedative, muscle relaxant and painkiller. It has been detected in overdoses and deaths in Scotland.

<p>PHS</p>	<p>Health, income and wealth in Scotland: A data profile in support of a health impact assessment of community wealth building - Health, income and wealth in Scotland: A data profile in support of a health impact assessment of community wealth building - Publications - Public Health Scotland</p>	<p>07/05/2024</p>	<p>This report presents data on health, income and wealth in Scotland, alongside baseline data for each of the five pillars of community wealth building. The report forms part of a health impact assessment on community wealth building, which will be published later this year.</p>
<p>AHRQ</p>	<p>Active Surveillance Culturing of Clostridioides difficile and Multidrug-Resistant Organisms: Methicillin-Resistant Staphylococcus aureus, Carbapenem-Resistant Enterobacterales, and Candida auris Effective Health Care (EHC) Program (ahrq.gov)</p>	<p>09/05/2024</p>	<p>Two new studies of high-risk patients (for Clostridioides difficile and carbapenem-resistant Enterobacterales) found that active surveillance culturing limited to high-risk patient populations could significantly reduce infections. However, these studies compared targeted screening to no screening. The effectiveness of targeted screening compared to universal screening remains unclear.</p>